Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP-asPNA Eye Drops for Antibiotic-Resistant Bacterial Keratitis
NCT06451172Phase 1Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GP-asPNA in bacterial keratitis, sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Bacteria testing outcome of the intervention eye at 90 days and Ophthalmic therapeutic effect of ASO eye drops at 90 days. Started Oct 2023; status: recruiting.
02
Drugs
GP-asPNA
03
Conditions
bacterial keratitis
Beyond the preview
Go deeper on NCT06451172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451172.